News Channels

28 Nov 2018 Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis
28 Nov 2018 Daiichi Sankyo Launches Antitumor Agent Trastuzumab Biosimilar for Intravenous Drip Infusions “Daiichi Sankyo” in Japan
28 Nov 2018 Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test
27 Nov 2018 Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies
27 Nov 2018 Forbius’ AVID200, a novel TGF-beta 1 & 3 Inhibitor, Cleared by the FDA to Commence Phase 1 Clinical Trial in Solid Tumors
27 Nov 2018 Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome
27 Nov 2018 Spirita Oncology, LLC Initiates a Phase 1 Clinical Trial of the Anti-Cancer Agent E6201 in Patients with Central Nervous System Metastases from BRAF+ or MEK-Mutated Metastatic Melanoma
27 Nov 2018 Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for Inflammatory Bowel Disease
27 Nov 2018 MicuRx Enrolls First Patient in a Phase 2 Clinical Trial in U.S. for Novel Antibiotic, Contezolid Acefosamil
27 Nov 2018 DNAtrix's Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial
27 Nov 2018 Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer
27 Nov 2018 Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company
27 Nov 2018 Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
27 Nov 2018 Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis
27 Nov 2018 OSE Immunotherapeutics Receives Belgian Authorization for a Phase 1 Clinical Trial to Evaluate Anti-IL-7 Receptor Antagonist OSE-127
27 Nov 2018 G1 Therapeutics Announces Positive Myelopreservation Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq® in First-Line Small Cell Lung Cancer
27 Nov 2018 Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
27 Nov 2018 Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo Plus Yervoy Vs. Placebo as A Maintenance Therapy in Patients with Extensive-Stage Small Cell Lung Cancer After Completion of First-Line Chemo
27 Nov 2018 FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
27 Nov 2018 Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up